Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321678 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
A Phase 2 study of T2DM (Type 2 Diabetes Mellitus), sponsored by Ascletis Pharma (China) Co., Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT07321678: Recruiting Phase 2 study of T2DM (Type 2 Diabetes Mellitus), sponsored by Ascletis Pharma (China) Co., Limited.
NCT07321678 is a Phase 2 study of T2DM (Type 2 Diabetes Mellitus) that is actively recruiting participants, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 100 participants, below the 210-participant average among 4 other T2DM (Type 2 Diabetes Mellitus) trials with a reported enrollment target (52% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07321678, a Phase 2 study of T2DM (Type 2 Diabetes Mellitus), is actively recruiting participants, sponsored by Ascletis Pharma (China) Co., Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ASC30 tablets
Study Locations (8)
California
- Ascletis Clinical Site - Riverside
- Ascletis Clinical Site - San Jose
Florida
- Ascletis Clinical Site - Miami
- Ascletis Clinical Site - Miami
Colorado
- Ascletis Clinical Site - Denver
Georgia
- Ascletis Clinical Site - Decatur
Missouri
- Ascletis Clinical Site - Springfield
Texas
- Ascletis Clinical Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT07321678 shows while recruiting
NCT07321678 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 210-participant average among 4 other T2DM (Type 2 Diabetes Mellitus) trials with a reported enrollment target (52% lower).
The record links to 1 condition, with T2DM (Type 2 Diabetes Mellitus) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07321678 lists 8 locations in 6 states (California, Florida, Colorado).
Frequently Asked Questions
What is clinical trial NCT07321678 about?
NCT07321678 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus". This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
What is the current status of trial NCT07321678?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-01. Estimated completion is 2026-08.
What conditions does trial NCT07321678 study?
This clinical trial studies the following conditions: T2DM (Type 2 Diabetes Mellitus).
What interventions are being tested in trial NCT07321678?
The interventions under investigation include: Placebo (DRUG), ASC30 tablets (DRUG).
Who is sponsoring clinical trial NCT07321678?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07321678 being conducted?
This trial has 8 study locations across California, Colorado, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T2DM (Type 2 Diabetes Mellitus)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia